Conversion surgery for gastric cancer: A cohort study from a western center

Paolo Morgagni, Leonardo Solaini, Massimo Framarini, Giovanni Vittimberga, Andrea Gardini, Domenico Tringali, Martina Valgiusti, Manlio Monti, Giorgio Ercolani

Research output: Contribution to journalArticle

Abstract

Background: Advanced unresectable gastric cancer has a dismal prognosis. The aim of this study was to evaluate the short- and long-term outcomes of patients who underwent induction chemotherapy ± gastrectomy for advanced gastric cancer. Material and methods: All patients referred to our center with a clinical diagnosis of unresectable locally advanced or stage IV gastric adenocarcinoma between April 2005 and August 2016 were included in the study. Cox regression was performed to find independent prognostic factor among the considered variable. Results: The cohort included 73 patients: 16 had best supportive care, 35 chemotherapy alone and 22 chemotherapy plus radical surgery. Thirty-three patients underwent surgery after chemotherapy. Twenty-two patients had R0 surgery, while the remaining 11 had only an exploratory procedure. Nine patients (40.9%) underwent gastrectomy plus hyperthermic intraperitoneal chemotherapy. Three patients out of 22 developed postoperative complications with a Clavien-Dindo grade above 2. Median survival was 50 months for patients who had chemotherapy plus surgery while it was 14 and 3 for those who had chemotherapy alone and best supportive care, respectively (p < 0.0001). Cox regression analysis performed on the whole cohort identified only radical conversion surgery as an independent factor positively associated with survival (HR 0.12, 95% CI 0.05–0.29, p < 0.0001). Conclusion: Conversion gastrectomy, when R0 could be achieved, is associated with long survivals and it is the most important prognostic factor in patients with advanced gastric cancer. Further studies are needed to define the ideal patient who can really benefit from this treatment.

Original languageEnglish
Pages (from-to)360-365
Number of pages6
JournalInternational Journal of Surgery
Volume53
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Stomach Neoplasms
Cohort Studies
Drug Therapy
Gastrectomy
Survival
Induction Chemotherapy
Stomach
Adenocarcinoma
Regression Analysis

Keywords

  • Conversion surgery
  • Gastrectomy
  • Induction chemotherapy
  • Unresectable gastric cancer

ASJC Scopus subject areas

  • Surgery

Cite this

Morgagni, P., Solaini, L., Framarini, M., Vittimberga, G., Gardini, A., Tringali, D., ... Ercolani, G. (2018). Conversion surgery for gastric cancer: A cohort study from a western center. International Journal of Surgery, 53, 360-365. https://doi.org/10.1016/j.ijsu.2018.04.016

Conversion surgery for gastric cancer : A cohort study from a western center. / Morgagni, Paolo; Solaini, Leonardo; Framarini, Massimo; Vittimberga, Giovanni; Gardini, Andrea; Tringali, Domenico; Valgiusti, Martina; Monti, Manlio; Ercolani, Giorgio.

In: International Journal of Surgery, Vol. 53, 01.05.2018, p. 360-365.

Research output: Contribution to journalArticle

Morgagni, P, Solaini, L, Framarini, M, Vittimberga, G, Gardini, A, Tringali, D, Valgiusti, M, Monti, M & Ercolani, G 2018, 'Conversion surgery for gastric cancer: A cohort study from a western center', International Journal of Surgery, vol. 53, pp. 360-365. https://doi.org/10.1016/j.ijsu.2018.04.016
Morgagni P, Solaini L, Framarini M, Vittimberga G, Gardini A, Tringali D et al. Conversion surgery for gastric cancer: A cohort study from a western center. International Journal of Surgery. 2018 May 1;53:360-365. https://doi.org/10.1016/j.ijsu.2018.04.016
Morgagni, Paolo ; Solaini, Leonardo ; Framarini, Massimo ; Vittimberga, Giovanni ; Gardini, Andrea ; Tringali, Domenico ; Valgiusti, Martina ; Monti, Manlio ; Ercolani, Giorgio. / Conversion surgery for gastric cancer : A cohort study from a western center. In: International Journal of Surgery. 2018 ; Vol. 53. pp. 360-365.
@article{167a7d0adbe642af87f1010e50683a39,
title = "Conversion surgery for gastric cancer: A cohort study from a western center",
abstract = "Background: Advanced unresectable gastric cancer has a dismal prognosis. The aim of this study was to evaluate the short- and long-term outcomes of patients who underwent induction chemotherapy ± gastrectomy for advanced gastric cancer. Material and methods: All patients referred to our center with a clinical diagnosis of unresectable locally advanced or stage IV gastric adenocarcinoma between April 2005 and August 2016 were included in the study. Cox regression was performed to find independent prognostic factor among the considered variable. Results: The cohort included 73 patients: 16 had best supportive care, 35 chemotherapy alone and 22 chemotherapy plus radical surgery. Thirty-three patients underwent surgery after chemotherapy. Twenty-two patients had R0 surgery, while the remaining 11 had only an exploratory procedure. Nine patients (40.9{\%}) underwent gastrectomy plus hyperthermic intraperitoneal chemotherapy. Three patients out of 22 developed postoperative complications with a Clavien-Dindo grade above 2. Median survival was 50 months for patients who had chemotherapy plus surgery while it was 14 and 3 for those who had chemotherapy alone and best supportive care, respectively (p < 0.0001). Cox regression analysis performed on the whole cohort identified only radical conversion surgery as an independent factor positively associated with survival (HR 0.12, 95{\%} CI 0.05–0.29, p < 0.0001). Conclusion: Conversion gastrectomy, when R0 could be achieved, is associated with long survivals and it is the most important prognostic factor in patients with advanced gastric cancer. Further studies are needed to define the ideal patient who can really benefit from this treatment.",
keywords = "Conversion surgery, Gastrectomy, Induction chemotherapy, Unresectable gastric cancer",
author = "Paolo Morgagni and Leonardo Solaini and Massimo Framarini and Giovanni Vittimberga and Andrea Gardini and Domenico Tringali and Martina Valgiusti and Manlio Monti and Giorgio Ercolani",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.ijsu.2018.04.016",
language = "English",
volume = "53",
pages = "360--365",
journal = "International Journal of Surgery",
issn = "1743-9191",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Conversion surgery for gastric cancer

T2 - A cohort study from a western center

AU - Morgagni, Paolo

AU - Solaini, Leonardo

AU - Framarini, Massimo

AU - Vittimberga, Giovanni

AU - Gardini, Andrea

AU - Tringali, Domenico

AU - Valgiusti, Martina

AU - Monti, Manlio

AU - Ercolani, Giorgio

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Advanced unresectable gastric cancer has a dismal prognosis. The aim of this study was to evaluate the short- and long-term outcomes of patients who underwent induction chemotherapy ± gastrectomy for advanced gastric cancer. Material and methods: All patients referred to our center with a clinical diagnosis of unresectable locally advanced or stage IV gastric adenocarcinoma between April 2005 and August 2016 were included in the study. Cox regression was performed to find independent prognostic factor among the considered variable. Results: The cohort included 73 patients: 16 had best supportive care, 35 chemotherapy alone and 22 chemotherapy plus radical surgery. Thirty-three patients underwent surgery after chemotherapy. Twenty-two patients had R0 surgery, while the remaining 11 had only an exploratory procedure. Nine patients (40.9%) underwent gastrectomy plus hyperthermic intraperitoneal chemotherapy. Three patients out of 22 developed postoperative complications with a Clavien-Dindo grade above 2. Median survival was 50 months for patients who had chemotherapy plus surgery while it was 14 and 3 for those who had chemotherapy alone and best supportive care, respectively (p < 0.0001). Cox regression analysis performed on the whole cohort identified only radical conversion surgery as an independent factor positively associated with survival (HR 0.12, 95% CI 0.05–0.29, p < 0.0001). Conclusion: Conversion gastrectomy, when R0 could be achieved, is associated with long survivals and it is the most important prognostic factor in patients with advanced gastric cancer. Further studies are needed to define the ideal patient who can really benefit from this treatment.

AB - Background: Advanced unresectable gastric cancer has a dismal prognosis. The aim of this study was to evaluate the short- and long-term outcomes of patients who underwent induction chemotherapy ± gastrectomy for advanced gastric cancer. Material and methods: All patients referred to our center with a clinical diagnosis of unresectable locally advanced or stage IV gastric adenocarcinoma between April 2005 and August 2016 were included in the study. Cox regression was performed to find independent prognostic factor among the considered variable. Results: The cohort included 73 patients: 16 had best supportive care, 35 chemotherapy alone and 22 chemotherapy plus radical surgery. Thirty-three patients underwent surgery after chemotherapy. Twenty-two patients had R0 surgery, while the remaining 11 had only an exploratory procedure. Nine patients (40.9%) underwent gastrectomy plus hyperthermic intraperitoneal chemotherapy. Three patients out of 22 developed postoperative complications with a Clavien-Dindo grade above 2. Median survival was 50 months for patients who had chemotherapy plus surgery while it was 14 and 3 for those who had chemotherapy alone and best supportive care, respectively (p < 0.0001). Cox regression analysis performed on the whole cohort identified only radical conversion surgery as an independent factor positively associated with survival (HR 0.12, 95% CI 0.05–0.29, p < 0.0001). Conclusion: Conversion gastrectomy, when R0 could be achieved, is associated with long survivals and it is the most important prognostic factor in patients with advanced gastric cancer. Further studies are needed to define the ideal patient who can really benefit from this treatment.

KW - Conversion surgery

KW - Gastrectomy

KW - Induction chemotherapy

KW - Unresectable gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=85045707456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045707456&partnerID=8YFLogxK

U2 - 10.1016/j.ijsu.2018.04.016

DO - 10.1016/j.ijsu.2018.04.016

M3 - Article

C2 - 29654967

AN - SCOPUS:85045707456

VL - 53

SP - 360

EP - 365

JO - International Journal of Surgery

JF - International Journal of Surgery

SN - 1743-9191

ER -